Therefore, we directly assessed the TMM status in the local cohort, using the TeloDIAG assay and retrieved 80% of ALT-positive samples, corresponding to 96% (N = 53) of IDH-mutant astrocytomas and 74% (N = 19) of histone-mutant gliomas, as expected. The gene discussed is GPT; the disease is central nervous system cancer.